Spiderwort Biotechnologies Inc. Marks 10 Years
Driving Regenerative Medicine Forward
OTTAWA, CANADA — August 26, 2025 — Spiderwort Biotechnologies Inc., a pioneering biotechnology company focused on developing biomaterials for regenerative medicine, this month celebrates ten years of innovation. Founded in August 2015 on the bold idea that cellulose-derived materials may help address complex medical challenges, the organization has evolved from a research initiative into a clinical-stage company.
“Reaching the ten-year mark in the competitive biotechnology industry marks a differentiating inflection point for our company which could not have been achieved without the dedication of our team, partners, investors, and advisors in the medical community.” Dr. Charles M. Cuerrier, CEO of Spiderwort Biotechnologies Inc., “We’ve matured our technology platform and advanced our investigational testing pipeline. Now, with strengthened manufacturing infrastructure, a modular cellulose-based platform strategy, and a rigorous approach to clinical development, we’re confident in our position for the decade ahead.”
Spiderwort Biotechnologies Inc. has made significant progress across infrastructure, capital growth, and regulatory milestone achievements including:
- Two investigational programs: CelluBridge®, a cellulose-based scaffold intended to support spinal cord injury applications and CelluJuve®, a novel cellulose-derived dermal filler intended for soft tissue augmentation in medical aesthetics.
- U.S. FDA Breakthrough Device Designation: Achieved special designation from the U.S. FDA to expedite the CelluBridge® spinal cord scaffold implant development, assessment, and review.
- Manufacturing infrastructure: Completed construction of an ISO 5 certified clean room to enable scaled production and clinical studies.
- Capital raised: Closed more than $20 million CAD to date, with plans to close additional funding this year.
- Regulatory milestones: Achieved ISO 10993 biocompatibility testing and Health Canada Investigational Testing Authorization (ITA) for CelluJuve® in 2025, enabling first-in-human clinical studies and soon-to-be announced milestones for CelluBridge® in 2025.
Through rigorous science in plant-derived scaffolds, manufacturing excellence, and thoughtful design for the clinic, Spiderwort Biotechnologies Inc. has translated breakthrough materials into a validated platform, built quality systems and scalable processes, and formed deep collaborations with clinicians and patients.
“Today, Spiderwort Biotechnologies Inc. is advancing two clinical-stage products that harness our proprietary biomaterials with the goal of promoting tissue repair and the restoration of function.” Dr. Andrew Pelling, Chief Science Officer at Spiderwort Biotechnologies Inc., “This journey reflects our core belief that inventive science, when paired with uncompromising execution, can deliver practical therapies with the potential to dramatically improve human health and well-being.”
The company’s near-term strategy is focused on advancing clinical development activities and manufacturing readiness. Priorities include its CelluJuve® clinical trial in Canada (with future geographic expansion under evaluation), advancing CelluBridge® toward clinical trials, extending capacity in clinical operations, regulatory affairs, and business development, expanding strategic partnerships in North America, Europe and APAC, and preparing for upcoming financing to support these milestones.
As Spiderwort Biotechnologies Inc. enters its second decade, the company will leverage its mature technology platform, manufacturing capabilities, and recent regulatory milestones to advance clinical evaluations. The company acknowledges the support of its advisory board, partners, investors, collaborators, and internal team for their role in navigating and advancing the mission to transform the future of regenerative medicine with cellulose-based biomaterials.
CelluJuve® is a device under development. While it has received Investigational Testing Authorization from Health Canada for clinical trials, it is not yet approved by Health Canada or the U.S. Food and Drug Administration (FDA) for commercial use, and it is not available for sale. The safety and effectiveness of CelluJuve® in humans has not been fully established and will be evaluated in upcoming clinical trials.For more information about Spiderwort Biotechnologies and CelluJuve®, please visit https://spiderwortbio.com/product/cellujuve/.
CelluBridge® is a device under development. It is not yet approved by Health Canada or the U.S. Food and Drug Administration (FDA) for commercial use, and it is not available for sale. The safety and effectiveness of CelluBridge® in humans has not been fully established and will be evaluated in upcoming clinical trials.For more information about Spiderwort Biotechnologies and CelluBridge®, please visit https://spiderwortbio.com/product/cellubridge/.
About Spiderwort Biotechnologies Inc.
Spiderwort is transforming biotechnology with a platform of cellulose-based biomaterials that serve as the scaffolds for the regenerative medicine of the future. Spiderwort’s biomaterials have shown promise in the treatment of spinal cord injuries and soft tissue regeneration. Spun out as a startup from the Pelling Lab, Spiderwort is led by CEO Charles M. Cuerrier and inspired by the work of CSO and TED Fellow Andrew E. Pelling. Learn more at spiderwortbio.com.
Media Contact
Shannon Murphy
s.murphy@spiderwortbio.com
613-808-5939